| Journal | Nature aging |
| Study Type | Cohort |
| Population | Human participants |
This study develops a new biological aging biomarker that integrates multiple data types including DNA methylation, which could help clinicians better assess patient health trajectories and mortality risk. The ability to quantify biological age from routine clinical lab data makes this potentially practical for widespread clinical use.
Researchers analyzed data from ~31,000 participants in the Mass General Brigham Biobank to develop EMRAge, a mortality risk biomarker derived from routine clinical laboratory values. They then created enhanced versions (DNAmEMRAge and OMICmAge) by incorporating DNA methylation and multi-omics data respectively. Both biomarkers demonstrated strong associations with chronic disease incidence, prevalence, and mortality across discovery (n=3,451) and validation cohorts (n=32,885 combined). Notably, OMICmAge can be calculated from DNA methylation data alone while incorporating proteomic, metabolomic, and clinical information.
“While biologically fascinating, I remain cautious about clinical implementation until we understand how this changes patient management decisions. The real test will be whether knowing someone’s ‘biological age’ leads to meaningful interventions that improve outcomes.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- What is OMICmAge and how does it differ from other aging biomarkers?
- How accurate is OMICmAge compared to existing biomarkers in predicting health outcomes?
- Can OMICmAge be implemented using existing clinical infrastructure?
- What clinical conditions can OMICmAge help predict or monitor?
- Is OMICmAge ready for routine clinical use?
FAQ
What is OMICmAge and how does it differ from other aging biomarkers?
OMICmAge is a multi-omics biological age biomarker that integrates DNA methylation, proteomic, metabolomic, and clinical data to predict mortality risk and chronic disease development. Unlike traditional aging biomarkers, OMICmAge can be calculated using only DNA methylation data while capturing information from multiple biological domains, making it more comprehensive yet practically feasible for clinical use.
How accurate is OMICmAge compared to existing biomarkers in predicting health outcomes?
In validation studies involving over 36,000 participants across multiple cohorts, OMICmAge performed comparably or better than current biomarkers in predicting mortality and chronic disease risk. The biomarker showed strong associations with both incident and prevalent chronic diseases across discovery and validation cohorts, demonstrating robust predictive performance.
Can OMICmAge be implemented using existing clinical infrastructure?
Yes, OMICmAge builds upon EMRAge, which was developed using routine clinical laboratory data from electronic medical records of ~31,000 participants. This foundation allows the biomarker to be broadly applicable across existing healthcare systems that maintain electronic medical records and can perform DNA methylation analysis.
What clinical conditions can OMICmAge help predict or monitor?
OMICmAge demonstrates strong associations with mortality risk and various chronic diseases, though the study doesn’t specify individual conditions. The biomarker’s multi-omics approach captures cellular and biochemical aging processes across multiple biological pathways, making it potentially useful for assessing overall health status and disease susceptibility.
Is OMICmAge ready for routine clinical use?
While OMICmAge shows promising results in large validation cohorts, it represents emerging research that requires further clinical validation before routine implementation. Healthcare providers should monitor developments in this field as the biomarker undergoes additional testing and regulatory evaluation for clinical applications.